Elucidata

Elucidata is the company behind Polly, an AI-ready omics data platform purpose-built for Pharma and BioPharma R&D teams. Polly centralises, harmonises, and prepares multi-omics, EHR, and imaging data for AI-driven research, enabling teams to accelerate target identification, biomarker discovery, and patient stratification. The platform is trusted by leading biopharma organisations including Janssen, Genentech, Alnylam, and more than 50 BioPharma teams worldwide.

By combining people, processes, and technology, Polly streamlines complex workflows, increases productivity, and delivers reusable, findable, and access-controlled AI-ready data products that power end-to-end decision support across the pharma value chain. The platform supports multimodal data integration and provides scalable, AI-powered infrastructure to accelerate drug discovery and development while delivering actionable insights.

Key Use Cases

• Target Identification: Rapidly identify and validate drug targets using harmonised multi-omics data and relevant public studies.
• Patient Stratification: Train machine learning classifiers on curated RNA-seq data to accurately segment patient cohorts for specific indications, achieving up to 3x faster insights from real-world evidence and omics data.
• Cell Type Annotation: Identify, extract, and annotate cell types or subtypes from single-cell datasets using custom marker lists.
• Signature Exploration: Leverage Polly's signature database to identify indications related to a gene signature or discover drugs that reverse a disease signature.
• Biomarker Prediction: Predict diagnostic or prognostic biomarkers by analysing bulk RNA-seq samples available on Polly.
• Meta-analysis: Integrate gene expression studies to identify target genes or enriched pathways within a selected indication.

Core Platform Capabilities

• Integrated Data Management: Seamlessly unifies EHRs, omics, imaging, and clinical trial data within a single platform, with LLM-powered metadata extraction and enrichment for high-quality insights.
• Scalable Infrastructure: Supports more than 26 data types and over 30 bioinformatics pipelines, enabling high-quality data processing with up to 4x cost reduction for foundation models.
• AI-driven Insights: Provides AI-assisted cohort builders and dashboards for faster decision-making, along with predictive modelling and visualisations to identify high-risk patients and recommend treatment plans.

Compliance, Security, and Standards

• SOC2, HIPAA, and GDPR compliant, ensuring secure and responsible data handling across all workflows.
• Active contributor to bioinformatics standards, including work on converting NCI CRDC data to the GA4GH Phenopacket Schema (presented at GLBIO 2024).

Proven Impact and Recognition

• Supported 17 therapies currently in clinical development.
• Delivered 4x acceleration in R&D milestones for partner organisations.
• Built more than 200 AI-ready data products for biopharma customers.
• Recognised by Fast Company as one of the Most Innovative Companies in Biotech in 2024.
• Praised by academic partners such as Northwestern University for delivering customised, quality-controlled single-cell data pipelines with scientific rigour and responsive project management.

Elucidata's Polly platform represents a comprehensive solution for biopharma R&D organisations seeking to unlock the full value of their biomedical data through trusted, scalable, and AI-ready infrastructure.